A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize ...

Now, the work presented at the 2025 annual EULAR congress in Barcelona adds two important pieces to the puzzle. First, a large-scale real-world study ...

Like in the STRIDE study of PAD, GLP-1s improved outcomes, but more work is needed to clarify who may benefit most.

Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in metabolic ...

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite ...

aThe First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China bLuoyang Key Laboratory of Clinical Multiomics and Translational ...

For patients with diabetes, exposure to GLP-1 RAs associated with increased risk for incident neovascular age-related macular degeneration.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

Sometimes, the right advances in medicine catch the public’s imagination—opening a world of possibilities that inspires ...

Univ. Lille, Inserm, Institut Pasteur de Lille, U1177─Drugs and Molecules for Living Systems, F-59000 Lille, France ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.